Editing Pfizer (section)

=== Oncology === 

Pfizer develops targeted therapies to treat multiple cancer types, including bladder, breast, cervical, lung, and colorectal cancers, as well as hematological malignancies. The company conducts research on [[Personalized medicine|precision medicine]] and [[immunotherapy]], aiming to improve survival rates and quality of life for cancer patients. Specially, the acquisition of Seagen has supported further development of oncology treatments, including mRNA cancer vaccines.<ref name="Driving equitable">{{cite web |title=Elif Aral: Driving equitable healthcare in the region |url=https://www.arabianbusiness.com/resources/elif-aral-driving-equitable-healthcare-in-the-region |date=22 October 2024|website=[[Arabian Business]] |access-date=30 March 2025}}</ref>

* '''Prostate Cancer''': The EMBARK trial showed improved metastasis-free survival in high-risk, non-metastatic prostate cancer patients, leading to the FDA approval of a combination therapy in 2023.<ref>{{cite web |title=Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer |author=Stephen J. Freedland, M.D., Murilo de Almeida Luz, M.D., Ugo De Giorgi, M.D., Ph.D., Martin Gleave, M.D., Geoffrey T. Gotto, M.D., M.P.H., Christopher M. Pieczonka, M.D., Gabriel P. Haas, M.D., Choung-Soo Kim, M.D., Miguel Ramirez-Backhaus, M.D., Antti Rannikko, M.D., Ph.D., Jamal Tarazi, M.D., M.P.A., Swetha Sridharan, M.B., B.S., Jennifer Sugg, M.S., Yiyun Tang, Ph.D., Ronald F. Tutrone, Jr., M.D., Balaji Venugopal, M.B., B.S., M.D., Arnauld Villers, M.D., Ph.D., Henry H. Woo, M.B., B.S., D.Med.Sc., Fabian Zohren, M.D., Ph.D., and Neal D. Shore, M.D. |url=https://www.nejm.org/doi/full/10.1056/NEJMoa2303974 |website=[[The New England Journal of Medicine]] |date=2023-10-18 |access-date=2025-03-30 |doi=10.1056/NEJMoa2303974}}</ref>

* '''The TALAPRO-2''' study explored treatments for metastatic prostate cancer with homologous recombination repair mutations, which are found in 25% of cases.<ref>{{cite web |title=Clinical Trials + Font Resize - Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC |url=https://www.pharmabiz.com/NewsDetails.aspx?aid=172947&sid=2 |website=Pharmabiz.com |date=11 October 2024|access-date=30 March 2025}}</ref>

* '''Bladder Cancer:''' The EV-302 study investigated new treatments for advanced urothelial cancer, focusing on improving care for hard-to-treat patient groups.<ref>{{cite web |title=PADCEV® (Enfortumab Vedotin-ejfv) with KEYTRUDA® (Pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer |url=https://www.urotoday.com/ev-302-te/articles.html?id=148585 |website=UroToday |access-date=30 March 2025}}</ref>